Competing interests
M.L.P. has served as a consultant for AbbVie, Almirall, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Eli Lilly, Framework for Interoperable Data Exchange (FIDE), Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, Trifecta Clinical/WCG, UCB and Zura Bio and as an investigator for AbbVie, AnaptysBio, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Bayer, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, OASIS Pharmaceuticals, Otsuka, Pfizer, Prometheus, Propeller Biosciences, Regeneron, Sanofi, Sonoma Biotherapeutics, UCB and Zura Bio. She has received royalties from Beth Israel Deaconess Medical Center and fellowship funding to the institution from AbbVie. A.M. has acted as a consultant, advisory board member and investigator for and received honoraria from AbbVie, Acelyrin, Amgen, Boehringer Ingelheim, Incyte, Johnson & Johnson, Legit Health, LEO Pharma, Eli Lilly, L’Oreal, MoonLake Immunotherapeutics, MSD, Novartis, Sandoz, Sanofi, Takeda and UCB. C.J.S. has acted as an investigator for AbbVie, AstraZeneca, ChemoCentryx, GlaxoSmithKline, Incyte, InflaRx, Novartis and UCB; reports consultancy fees from AbbVie, Alumis, AstraZeneca, InflaRx, Incyte, Logical Images, Oruka Therapeutics, Sonoma Biotherapeutics and UCB; and has acted as a speaker for AbbVie and Novartis. F.G.B. has received honoraria for participation in advisory boards, in clinical trials and/or as a speaker from AbbVie, AbbVie Deutschland GmbH & Co. KG, Acelyrin, Almirall, Avalo, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Citryll, Incyte, Inflax, Janssen-Cilag GmbH, Johnson & Johnson, Eli Lilly, Merck, Mölnlycke, MoonLake Immunotherapeutics, Navigator Medicines, Novartis, Sanofi, Sitala, Takeda and UCB. H.L.-T. is the founder, owns stock in and has a podcast for Learnskin.com; has served as a consultant for Hidramed Solutions, Insmed, MoonLake Immunotherapeutics, Next Science, Novartis and UCB; has been a speaker for Incyte and UCB; has participated in trials for Incyte, Eli Lilly, Medline, Mölnlycke, MoonLake Immunotherapeutics, Novartis, Sigvaris, Solascure, Tissue Tech and UCB; has received research support from Essity, Next Science, Sigvaris and Vomaris; and is a Q10 Board of Directors member for the HS Foundation. J.L.H. is on the board of directors of the Hidradenitis Suppurativa Foundation and has served as an advisor, investigator and/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Insmed, LEO Pharma, MoonLake Immunotherapeutics, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Regeneron, Sanofi, Spyre Therapeutics and UCB. J.W.F. has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, ChemoCentryx, AbbVie, Azora, Novartis and UCB; has participated in trials for Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, CSL Behring and Azora; and has received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche-Posay. Z.R. has received honoraria (investigator/speaker or advisory boards) from AbbVie, Almirall, Alumis, Amgen, Bayer, Boehringer Ingelheim, Celltrion, Incyte, Galderma, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Regeneron, Sanofi and UCB. M.J.G. is an investigator, speaker and/or advisor for AbbVie, Akros, Alumis, Amgen, AnaptysBio, Arcutis, Aristea, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, MoonLake Immunotherapeutics, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Sun Pharma, Takeda, Tarsus, UCB, Union, Vyne and Vyntex. N.G. has participated in clinical trials with AbbVie, Pfizer, ChemoCentryx and Incyte; served on advisory boards and consulted for Novartis, Boehringer Ingelheim, Sonoma Biotherapeutics, UCB and MoonLake Immunotherapeutics; received research support from Novartis and DeepX Health; and currently serves on the board of directors for the HS Foundation. H.H.v.d.Z. has received consultancy fees and lecture honoraria from AbbVie, Incyte, InflaRx, Insmed, Novartis and UCB. V.d.M. has no conflicts of interest to declare. A.V.M. reports consultancy/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. B.D.E. has served as a speaker, advisor and/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Celldex, Concert, Dermavant, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, LEO Pharma, Merck, Navigator Medicines, Novartis, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB and Ventyx. L.S.A. has served as a speaker, advisor and/or investigator for AbbVie, Alumis, Amgen, Apollo Therapeutics, arGEN-X, AstraZeneca, Biofrontera AG, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, ChemoCentryx, CorEvitas, Corrona, DermTech International, Eli Lilly, Exact Sciences, GlaxoSmithKline Immunology, Helsinn Healthcare, IgGenix, Incyte, Janssen, Kymera Therapeutics, Kyowa Kirin, LEO Pharma, Lilly ICOS, Merck, Mindera, Novartis, Pfizer, Regeneron, Replimune, Sanofi, Soligenix, Sun Pharma, Takeda, Timber Pharmaceuticals, Trevi Therapeutics, UCB, VeraDermics and Zura Bio. K.H. reports consultancy/advisory board honoraria from AbbVie, Boehringer Ingelheim, Novartis and Sanofi. He has received speaker fees/grants from AbbVie, Boehringer Ingelheim, Eisai, Novartis, Sanofi and UCB. C.T., J.K., H.Z., J.S.K., K.B. and L.L.S. are employees and shareholders of Incyte. C.C.Z. reports consultancy/advisory board disease-relevant honoraria from Almirall, Boehringer Ingelheim, Eli Lilly, Idorsia, Incyte, MSD, Novartis, Pfizer, Sanofi, Takeda, UCB and Zura Bio. He has received speaker fees from Bristol Myers Squibb, Novartis and UCB; is president of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV; is editor of EADV News; and is co-copyright holder of IHS4 on behalf of the EHSF e.V.
